NicOx S.A. has achieved the first milestone in its agreement with Merck in the antihypertensive field, resulting in a $6.5 million milestone payment to NicOx. The milestone was linked to the initiation of GLP toxicology studies on the first development candidate selected by the two companies. This milestone represents an important step towards filing an IND and clinical development of this compound. Michele Garufi, chairman and chief executive officer of NicOx, said, “We are very plea...